Human C-reactive protein does not promote atherosclerosis in transgenic rabbits

Circulation

Volumn 120, Issue 21, 2009, Pages 2088-2094

  Koike, Tomonari ^a   Kitajima, Shuji ^b   Yu, Ying ^a   Nishijima, Kazutoshi ^b   Zhang, Jifeng ^a,c   Ozaki, Yukio ^a   Morimoto, Masatoshi ^d   Watanabe, Teruo ^e   Bhakdi, Sucharit ^f   Asada, Yujiro ^g   Chen, Y Eugene ^c   Fan, Jianglin ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d KUMAMOTO HEALTH SCIENCE UNIVERSITY   (Japan)

^e FUKUOKA WAJIRO HOSPITAL   (Japan)

^f Institute of Medical Microbiology and Hygiene   (Germany)

^g UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Atherosclerosis; Cardiovascular disease; Coronary disease; Pathology; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CELL PROLIFERATION; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE PREDISPOSITION; FEEDING; FEMALE; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN ISOLATION; RABBIT; SMOOTH MUSCLE FIBER; TRANSGENIC ANIMAL; WESTERN BLOTTING;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, DIETARY; HUMANS; MALE; RABBITS;

EID: 73449134794     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.872796     Document Type: Article

References (39)

1. Nilsson J. CRP: marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol. 2005;25:1527-1528.
2. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-1812.
3. Schunkert H, Samani N. Elevated C-reactive protein in atherosclerosis: chicken or egg? N Engl J Med. 2008;359:1953-1955.
4. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, Smeeth L, Deanfield JE, Lowe GD, Rumley A, Fowkes FG, Humphries SE, Hingorani AD. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38:217-231.
5. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008;264:295-314.
6. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129-2138.
7. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135-2150.
8. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem. 2009;55:229-238.
9. Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysio-logical significance. Am J Pathol. 2005;167:1139-1148.
10. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AJ, Kastelein J, Koenig W, Libby P, Lorenzatti A, MacFadyen J, Nordestgaard B, Shepherd J, Willerson J, Glynn R, Group JS. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
11. Jialal I, Devaraj S. Jupiter to earth: CRP promotes atherothrombosis. Metab Syndr Relat Disord. 2009;7:1-3.
12. Fuster V, Bansilal S. JUPITER strikes earth. Nat Clin Pract Cardiovasc Med. 2009;6:159.
13. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apo-lipoprotein E-deficient mice. Circulation. 2004;109:647-655.
14. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, Majid-Hassan E, Oparil S, Szalai AJ. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol. 2008;172:22-30.
15. Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM, Emeis JJ. No effect of C-reactive protein on early atherosclerosis development in apoli-poprotein E*3-leiden/human C-reactive protein transgenic mice. Arte-rioscler Thromb Vasc Biol. 2005;25:1635-1640.
16. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 2005;102:8309-8314.
17. Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M, Blettner M, Bhakdi S. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol. 2005;25:1641-1646.
18. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/-mice. Atherosclerosis. 2008;196:248-255.
19. Torzewski M, Reifenberg K, Cheng F, Wiese E, Kupper I, Crain J, Lackner KJ, Bhakdi S. No effect of C-reactive protein on early atherosclerosis in LDLR-/-/human C-reactive protein transgenic mice. Thromb Haemost. 2008;99:196-201.
20. Kovacs A, Tornvall P, Nilsson R, Tegner J, Hamsten A, Bjorkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA. 2007;104:13768-13773.
21. Pepys MB, Baltz M, Gomer K, Davies AJ, Doenhoff M. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature. 1979;278: 259-261.
22. Fan J, Watanabe T. Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol Ther. 2003;99:261-282.
23. Kushner I, Feldmann G. Control of the acute phase response: demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J Exp Med. 1978;148:466-477.
24. Anderson HC, McCarty M. The occurrence in the rabbit of an acute phase protein analogous to human C reactive protein. J Exp Med. 1951;93:25-36.
25. Fan J, Wang J, Bensadoun A, Lauer SJ, Dang Q, Mahley RW, Taylor JM. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci USA. 1994;91:8724-8728.
26. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Gaszner M, Felsenfeld G. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci U S A. 2002;99:6883-6888.
27. Fan J, Unoki H, Kojima N, Sun H, Shimoyamada H, Deng H, Okazaki M, Shikama H, Yamada N, Watanabe T. Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 2001;276:40071-40079.
28. Chiesa G, Hobbs HH, Koschinsky ML, Lawn RM, Maika SD, Hammer RE. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J Biol Chem. 1992;267:24369-24374.
29. Fan J, Ji ZS, Huang Y, de Silva H, Sanan D, Mahley RW, Innerarity TL, Taylor JM. Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma. J Clin Invest. 1998;101:2151-2164.
30. Liang J, Liu E, Yu Y, Kitajima S, Koike T, Jin Y, Morimoto M, Hatakeyama K, Asada Y, Watanabe T, Sasaguri Y, Watanabe S, Fan J. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation. 2006;113:1993-2001.
31. Hirata M, Watanabe T. Regression of atherosclerosis in normotensive and hypertensive rabbits: a quantitative analysis of cholesterol-induced aortic and coronary lesions with an image-processing system. Acta Pathol Jpn. 1988;38:559-575.
32. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nor-destgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-1908.
33. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollen-weider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37-48.
34. Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysio-logical significance. Am J Pathol. 2005;167:1139-1148.
35. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
36. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
37. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190: 1733-1740.
38. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003; 108:512-515.
39. Shiomi M, Ito T, Yamada S, Kawashima S, Fan J. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbits). Arterioscler Thromb Vasc Biol. 2003;23:1239-1244.